Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Cabotegravir/rilpivirine (CAB/RPV), sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.
Read the full article on WikipediaHIV infection Clinical criteria: Patient must be virologically suppressed on a stable antiretroviral regimen for at least 6 months, AND The treatment must be in combination with rilpivirine tablets, AND Patient must intend to proceed to treatment with intramuscular administration of cabotegravir and rilpivirine.
“Cabotegravir is an integrase strand transfer inhibitor. This means it blocks the HIV's enzyme integrase, thereby preventing its genome from being integrated into the human cells' DNA. As this is a necessary step for the virus to replicate, its further spread is hampered.”
“tablets: 41 hoursinjection: 5.6–11.5 weeks”
Working under the parallel aged-care framework? Aged-care equivalent →